IdiPAZ-CNIO Pediatric Onco-Hematology Clinical Research Unit

Home | Research & Innovation | Scientific Programmes | Clinical Research Programme | IdiPAZ-CNIO Pediatric Onco-Hematology Clinical Research Unit

Antonio Pérez
Antonio Pérez Head of Clinical Research Unit
T +34 917328000 (Ext )
anperezm@ext.cnio.es

Research Scientists

  • Víctor Galán

Clinical Investigator

  • Carmen Mestre

Post-Doctoral Fellows

  • Cristina Aguirre
  • Alfonso Alba
  • Halin Bareke
  • Elisa Pilar Izquierdo
  • Adriana Mañas
  • Jordi Minguillón
  • Andrés París
  • Odelaisy León Triana

Graduate Students

  • Karima Al Akioui
  • Álvaro Blázquez
  • Laura Clares
  • María Octavia de Santisteban
  • Esther Díaz Maroto
  • Mikel Fernández
  • Sara Fernández
  • Beatriz García
  • Adrián Ibáñez
  • Marta Ibáñez
  • Beatriz Madroñal
  • Alicia Martín
  • Andrea Matesanz
  • Antonio Jesús Muñoz
  • Sara Naharro
  • Alfonso Navarro
  • Beatriz Ruz
  • Cristina Smith
  • Claudia Suanzes
  • Clara Venegas

Technicians

  • Estefania Ayala
  • Lidia Pertiñez
  • Natalia Riestra

The Pediatric Onco-Hematology Clinical Research Unit, headed by Antonio Pérez-Martínez, comprises a multidisciplinary team of physicians, geneticists, biologists, biochemists, and bioinformaticians, who, for the past decade, have carried out projects ranging from knowledge generation to direct clinical application through the development of clinical trials. Our research, which is mostly funded by Fundación Cris Contra el Cáncer, focuses on the design of therapies applied to paediatric oncology, infectious diseases, and paediatric transplantation. Briefly, our research interests include: 1) the use of haematopoietic stem cell transplantation as a platform for cell therapy; 2) the improvement of human stem cell progenitors transplantation in children; 3) cell therapy with memory T lymphocytes as adoptive immunotherapy; and 4) the use of both activated and memory-like NK cells and CART-T cells in paediatric oncology. Together with this, we led several projects aimed at studying the efficacy and feasibility of cell therapy against infectious diseases. Finally, we are also working on the induction of immunological tolerance in solid organ transplantation by inducing mixed haematopoietic chimera through cell therapy. We maintain a strong commitment to patients and to improving their quality of life, having a direct impact on society’s well-being. In this sense, we have several active academic clinical trials and collaborations with industry, with the objective of developing new and more effective therapies with fewer side effects.

Publications

Up

CNIO
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.